drugset / Trial / NCT04925661
HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia
Phase 1
Completed
40 enrolled
Sunshine Lake Pharma Co., Ltd.
Nicoya Therapeutics (Shanghai) Co., Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the safety, tolerability , pharmacokinetics and Preliminary Efficacy of HEC53856 Capsules in Patients With Non-dialysis Renal Anemia.
Timeline
- Start
- 2021-11-04
- Primary completion
- 2023-08-29
- Completion
- 2023-08-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HEC53856 | Unknown | 100 mg | — |
| Subject | HEC53856 | Unknown | 150 mg | — |
| Subject | HEC53856 | Unknown | 200 mg | — |
| Comparator | Roxadustat | Small molecule | 70 mg | — |